Psilocybin-containing mushroom-assisted psychotherapy is associated with sustained psychological and somatic...

We report two case studies that examine the therapeutic potential of structured psilocybin-containing mushroom biomass regimens administered within a clinical framework, evaluating their impact on mental health outcomes as well as associated somatic symptoms. Two patients underwent the De La Haye Psilocybin Treatment Protocol (DPTP), which integrates micro- and high-doses (combined psilocybin and psilocin content of 1-2 mg versus 40-60 mg) with psychohistoriographic psychotherapy. Follow-up included an integration session and subsequent office visits, including the completion of the Revised Mystical Experience Questionnaire (MEQ-30) two months post-treatment. Case 1 described a 29-year-old female with social anxiety, self-criticism, chronic musculoskeletal pain, and a recent diagnosis of diabetes. Post-treatment, she reported reduced shame, increased self-confidence, and substantial reductions in pain severity. Case 2 involved a 44-year-old female presenting with depression, hopelessness, and long-COVID-related anosmia and ageusia. She reported enhanced psychological resilience, improved mood, and resolution of diffuse body aches. Following the therapeutic dose, she also reported a 80-90% recovery of smell and taste after three years of dysfunction, post COVID-19 infection. The MEQ-30 scores were both high, indicating profound mystical-type experiences. These cases demonstrate improvements in psychological and somatic symptoms following participation in the DPTP. While the pain reduction and observed recovery of olfactory and gustatory function is noteworthy, spontaneous improvements cannot be excluded and further controlled investigation is warranted.